Small Interfering Ribonucleic Acid (RNA) Market Report 2026

Small Interfering Ribonucleic Acid (RNA) Market Overview

• Small Interfering Ribonucleic Acid (RNA) market size has reached to $18.86 billion in 2025 • Expected to grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20% • Growth Driver: Rise In Demand For Personalized Medicine Fueling The Growth Of The Maret Due To Targeted Gene Silencing And Improving Therapeutic Outcomes • Market Trend: Novel Gene-Silencing Approaches Provide Sustained Effects With Reduced Dosing • North America was the largest region in 2025.

What Is Covered Under Small Interfering Ribonucleic Acid (RNA) Market?

Small interfering ribonucleic acid (RNA) is a short, double-stranded RNA molecule that plays a key role in gene silencing through a process called RNA interference (RNAi). It binds to complementary messenger RNA (mRNA) sequences, leading to their degradation and preventing protein synthesis. The primary purpose of siRNA is to regulate or suppress the expression of specific genes, often used in research and therapeutic applications to target disease-causing genes. The main types of small interfering ribonucleic acid (RNA) include liposome systemic therapy and nanoparticle-based systemic therapy. Liposome systemic therapy refers to a drug delivery approach that uses liposomes to transport therapeutic agents throughout the body via the bloodstream. These are indicated for various conditions, including cardiovascular diseases, respiratory diseases, oncology, neurodegenerative diseases, and infectious diseases, serving end users such as hospitals, research institutions, pharmaceutical and biotechnology companies, and academic institutions.

What Is The Small Interfering Ribonucleic Acid (RNA) Market Growth Forecast?

The small interfering ribonucleic acid (rna) market size is expected to see exponential growth in the next few years. It will grow to $47.07 billion in 2030 at a compound annual growth rate (CAGR) of 20.0%. The growth in the forecast period can be attributed to increasing regulatory approvals for rna therapies, growing demand for personalized medicine, expansion of nanoparticle delivery innovations, rising investments by pharmaceutical companies, broader application of sirna in infectious and rare diseases. Major trends in the forecast period include increasing clinical adoption of rna interference therapies, growing focus on targeted gene silencing approaches, expansion of advanced sirna delivery platforms, rising investment in precision therapeutics development, enhanced emphasis on scalable rna manufacturing.

Global Small Interfering Ribonucleic Acid (RNA) Market Segmentation

1) By Type: Liposome Systemic Therapy, Nanoparticle-Based Systemic Therapy 2) By Indication: Cardiovascular Diseases, Respiratory Diseases, Oncology, Neurodegenerative Diseases, Infectious Diseases 3) By End-User: Hospital, Research Institutions, Pharmaceutical And Biotechnology Companies, Academic Institutions Subsegments: 1) By Liposome Systemic Therapy: Cationic Liposome Delivery, Neutral Liposome Delivery, Pegylated Liposome Delivery, Targeted Liposome Delivery 2) By Nanoparticle-Based Systemic Therapy: Lipid Nanoparticle Delivery, Polymer Nanoparticle Delivery, Gold Nanoparticle Delivery, Silica Nanoparticle Delivery

What Is The Driver Of The Small Interfering Ribonucleic Acid (RNA) Market?

The rise in demand for personalized medicine is expected to propel the growth of the small interfering ribonucleic acid (RNA) market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Small interfering ribonucleic acid (siRNA) enhances personalized medicine by enabling targeted gene silencing, making it ideal for treating specific genetic disorders and diseases. It reduces off-target effects by precisely inhibiting disease-causing mRNA, improving therapeutic efficacy and patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rise in demand for personalized medicine is driving the growth of the small interfering ribonucleic acid (RNA) industry.

Key Players In The Global Small Interfering Ribonucleic Acid (RNA) Market

Major companies operating in the small interfering ribonucleic acid (rna) market are Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Sanofi S.A., Sarepta Therapeutics Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Silence Therapeutics plc, Arrowhead Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Arbutus Biopharma Corporation, Evox Therapeutics Ltd., Phio Pharmaceuticals Inc., Genecon Biotechnologies Co. Ltd., Olix Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals Inc., Sirnaomics Ltd.

Global Small Interfering Ribonucleic Acid (RNA) Market Trends and Insights

Major companies operating in the small interfering ribonucleic acid (siRNA) therapeutics market are focusing on securing regulatory approvals for novel mechanisms to treat rare genetic diseases, aiming to provide sustained effects and reduce dosing frequency for patients. Regulatory approvals are official clearances from authorities allowing a drug or therapy to be safely tested, marketed, or used in patients. For instance, in March 2025, Alnylam Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Qfitlia (fitusiran), the first small interfering ribonucleic acid (siRNA)-based therapy for adults and adolescents aged 12 years and older with hemophilia A or B, with or without inhibitors. It is designed to lower antithrombin levels, thereby enhancing thrombin generation to promote clot formation and reduce bleeding episodes. Qfitlia offers a subcutaneous, once-every-two-month dosing regimen providing a novel, non-factor therapeutic option for hemophilia management.

What Are Latest Mergers And Acquisitions In The Small Interfering Ribonucleic Acid (RNA) Market?

In May 2025, AbbVie Inc., a US-based biopharmaceutical company, partnered with ADARx Pharmaceuticals Inc. Through this partnership, AbbVie Inc. aims to integrate ADARx Pharmaceuticals Inc.’s proprietary RNA technology with its scientific expertise to develop next-generation small interfering RNA (siRNA) therapies, enhancing advancements in neuroscience, immunology, and oncology. ADARx Pharmaceuticals Inc. is a biotechnology company developing small interfering ribonucleic acid (siRNA)-based therapies that target specific mRNA to treat diseases.

Regional Insights

North America was the largest region in the small interfering ribonucleic acid (RNA) market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Small Interfering Ribonucleic Acid (RNA) Market?

The small interfering ribonucleic acid (RNA) market consists of revenues earned by entities by providing services such as gene silencing assays, delivery system development, molecular diagnostics, preclinical testing, and laboratory research support. The market value includes the value of related goods sold by the service provider or included within the service offering. The small interfering ribonucleic acid (RNA) market also includes sales of synthesis kits, lipid nanoparticles, delivery vectors, RNAi assay kits, transfection reagents, and RNA extraction kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Small Interfering Ribonucleic Acid (RNA) Market Report 2026?

The small interfering ribonucleic acid (rna) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the small interfering ribonucleic acid (rna) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.